PRESS STATEMENTS11.24.2021 Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia11.12.2021 Pfizer Names Bill Sessa, Ph.D., Chief Scientific Officer to Lead Internal Medicine Research11.09.2021 PFIZER AND BIONTECH SUBMIT REQUEST TO AMEND U.S. FDA EMERGENCY USE AUTHORIZATION OF THEIR COVID-19 VACCINE BOOSTER TO INCLUDE ALL INDIVIDUALS 18 AND OLDER10.18.2021 New Formulation of COMIRNATY® Receives Positive Opinion from CHMP10.15.2021 Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY®10.04.2021 Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union09.16.2021 Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content09.06.2021 Pfizer and BioNTech Submit a Variation to EMA with the Data in Support of a Booster Dose of COMIRNATY®09.03.2021 The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis® Patents09.01.2021 FDA Issues Drug Safety Communication Related to Current XELJANZ® Label09.01.2021 First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness08.13.2021 Pfizer Expands Voluntary Nationwide Recall to include Four Additional Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content07.28.2021 Pfizer and BioNTech Share Detailed Update to the Results from 6 Month Safety and Efficacy Data Analysis of Landmark COVID-19 Vaccine Study07.16.2021 Pfizer Issues A Voluntary Nationwide Recall for Twelve Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content07.16.2021 U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine07.08.2021 Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant07.08.2021 Newly Published Expert Opinion Article Details Evidence for Classifying Aging Immune System as a High-Risk Condition for Pneumococcal Vaccine Policy06.11.2021 XELJANZ® Safety Review Recommendation Issued in the European Union05.28.2021 Pfizer Colleagues To Mentor Veterans In Transition To Civilian Life05.11.2021 Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition Associated with Progressive HPagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8Next pageNext ›Last pageLast »Press Release ArchivePress StatementsPodcastsScience Will WinThe Antigen PodcastThe Antigen Podcast Season 1The Antigen Podcast Episode 1: Vaccines 101The Antigen Podcast Episode 2: The History of VaccinesThe Antigen Podcast Episode 3: Global Perspectives, Barriers & SolutionsThe Antigen Podcast Episode 4: Vaccine Hesitancy Part 1The Antigen Podcast Episode 5: Vaccine Hesitancy Part 2The Antigen Podcast Episode 6: Vaccine Politics, Policy & AdvocacyThe Antigen Podcast Episode 7: Innovations in the Vaccine LandscapeThe Antigen Podcast Episode 8: What's Next?The Antigen Podcast Season 2The Antigen Podcast Episode 1: #COVID19 Looking Back to Look ForwardThe Antigen Podcast Episode 2: #COVID19 What Do We Do in the Meantime?The Antigen Podcast Episode 3: #COVID19 The Quest for a VaccineThe Antigen Podcast Episode 4: #COVID19 Teamwork Makes the Dream WorkDiverse Perspectives Podcastmenopause: unmutedHemcastContact Media RelationsPress Kits & DownloadsCompany Press KitPfizer Oncology Press KitPSA NarrativeRare Disease Gene Therapy Press KitATTR-Amyloidosis Press KitUC NarrativeEczema Inside Out Press KitOnline Pfizer Press KitCompany Press KitView the Pfizer Company Press KitPress StatementsView Pfizer's latest press statements Related ArticlesOur PurposePfizer's Commitment to Supplier DiversityOur PurposeCarbon Neutral by 2030: How Pfizer is Fighting Climate Change…Your HealthAnatomy of a Clinical Trial: The Purpose, People, and Phases of…Our ProductsShot of a Lifetime: How Two Pfizer Manufacturing Plants Upscaled…Our ProductsShot of a Lifetime: How Pfizer Developed its Own Raw Materials…Our ProductsShot of a Lifetime: How Pfizer and BioNTech Developed and…Our ProductsShot of a Lifetime: How Pfizer is Partnering with CMOs to…Your HealthWhy Raising Health Literate Children Is ImportantOur PurposeReasons to Reject H.R. 3Your HealthThe Truth About COVID-19 and Black FungusOur PurposeHow We’re Partnering to Improve Health Outcomes for Black YouthOur ScienceContinuing to Follow the Science: An Open Letter from Pfizer…Our PurposeWhy Foreign Drug Pricing Policies Don’t WorkOur PeopleRamcess Jean-Louis Is Ready to Build on Pfizer’s Longtime…Our PurposeThrough Public-Private Partnership, Scientists are Working to…Our PurposeAiming for Equity: Assessing Pfizer's Ongoing Commitment to…Our PeopleThanking John Young for His Years of Service to Pfizer – and to…Our PurposeIncreased Access to Biosimilars Could Save the U.S. Healthcare…Your HealthTranslating Technical Language into Plain Language for Clinical…Our PurposeHow 10 Biopharma Companies are Working Together to Bring…Our PeopleView for the FutureShowHide
![iStock-1199449498_380x300[1].jpg](https://cdn.pfizer.com/pfizercom/styles/style_300_170/s3/2021-09/iStock-1199449498_380x300%5B1%5D.jpg?pYyJpQdhyvaU22v13JPyau8ro2rGk0CR&itok=pJGCW7Vt)
